Chemical Reprogramming of Somatic Cells to Insulin-Producing Cells

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for directly converting somatic cells into insulin-producing cells often require artificial gene transfer, whereas the goal is to achieve this conversion using small molecule compounds without gene manipulation.

Innovation Solution

Culturing somatic cells in the presence of specific small molecule compounds such as cAMP inducers, GSK3 inhibitors, TGF-β inhibitors, BMP inhibitors, p53 inhibitors, PI3K inhibitors, Notch inhibitors, and RAR agonists to induce differentiation into insulin-producing cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If artificial gene transfer is used to convert somatic cells into insulin-producing cells, then the conversion efficiency is improved, but the complexity of the process and safety concerns increase

Engineering Contradiction:

Improveconversion efficiencyVSAvoidprocess complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent replaces the mechanical/genetic engineering approach (gene transfer) with a chemical approach (small molecule compounds). Instead of introducing foreign genes into somatic cells, the invention uses a combination of small molecule inhibitors and inducers to chemically reprogram somatic cells into insulin-producing cells, thereby eliminating the need for complex gene transfer machinery and reducing process complexity

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent changes the chemical parameters of the culture system by introducing specific small molecule compounds (GSK3 inhibitor, TGF-β inhibitor, BMP inhibitor, p53 inhibitor, PI3K inhibitor, Notch inhibitor, and RAR agonist) to alter the cellular differentiation pathway. This chemical parameter modification enables direct conversion of somatic cells to insulin-producing cells without genetic modification

Inventive Principle:

Principle #35Parameter changes

2Reliability

If artificial gene transfer is used to produce insulin-producing cells, then the functional capability is improved, but the safety and ethical concerns worsen

Engineering Contradiction:

Improvefunctional capabilityVSAvoidsafety concerns

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent substitutes gene transfer technology with chemical reprogramming using small molecule compounds. This replacement eliminates the safety risks associated with genetic modification, such as insertional mutagenesis, immunogenicity of viral vectors, and off-target effects, while maintaining the ability to generate functional insulin-producing cells

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent uses small molecule compounds that can be easily added and removed from the culture system, unlike genetic modifications which are permanent and difficult to reverse. The chemical reprogramming agents can be disposed of after use, leaving no permanent genetic alteration in the cells, thereby improving safety for therapeutic applications

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Productivity

If multiple small molecule compounds are used to induce differentiation, then the production of insulin-producing cells is improved, but the complexity of the composition increases

Engineering Contradiction:

Improveproduction of insulin-producing cellsVSAvoidcomposition complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent segments the differentiation process into distinct stages, each targeted by specific small molecule compounds. The composition includes inhibitors (GSK3, TGF-β, BMP, p53, PI3K, Notch) and agonists (RAR) that act on different signaling pathways at different times during reprogramming, allowing systematic control of the complex differentiation process while maintaining manageability

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent uses small molecule compounds that can be applied to various types of somatic cells to generate insulin-producing cells. The same composition strategy (combination of inhibitors and inducers) works across different cell sources, providing a universal approach that simplifies the overall process despite the complexity of individual compound actions

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS12018283B2Method for producing insulin-producing cells

Publication Date: 2024.06.25 KATAOKA

AI summary

The present invention chiefly aims to provide a process for directly inducing insulin-producing cells from somatic cells without performing artificial gene transfer. The present invention can include a process for producing an insulin-producing cell by inducing differentiation directly from a somatic cell, the process comprising a step of culturing the somatic cell in the presence of a cAMP inducer, and six members selected from the group consisting of a GSK3 inhibitor, a TGF-β inhibitor, a BMP inhibitor, a p53 inhibitor, a PI3K inhibitor, a Notch inhibitor and a RAR agonist, or all members thereof. The insulin-producing cells obtained by the present invention are useful in regenerative medicine and the like.